Quarterly report [Sections 13 or 15(d)]

Fair Value Measurements (Tables)

v3.25.3
Fair Value Measurements (Tables)
9 Months Ended
Sep. 30, 2025
Fair Value Measurements  
Schedule of financial assets and liabilities measured at fair value on a recurring basis

The following tables set forth the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands):

Fair Value Measurements as of September 30, 2025 using:

Quoted Prices in

Significant Other

Significant

Active Markets for

Observable

Unobservable

Identical Assets

Inputs

Inputs

(Level 1)

(Level 2)

(Level 3)

Total

Assets:

Cash equivalents:

Money market funds

$

8,805

$

$

$

8,805

U.S. treasury bills

26,202

26,202

Total cash equivalents

35,007

35,007

Investment in equity securities

1,521

1,521

Exarafenib milestone asset (Note 6)

3,500

3,500

Castle Creek PRV Interest (Note 4)

Castle Creek warrants (Note 4)

595

595

Total financial assets

$

36,528

$

$

4,095

$

40,623

Liabilities:

Exarafenib milestone contingent consideration (Note 6)

$

$

$

3,500

$

3,500

Total financial liabilities

$

$

$

3,500

$

3,500

Fair Value Measurements as of December 31, 2024 using:

Quoted Prices in

Significant Other

Significant

Active Markets for

Observable

Unobservable

Identical Assets

Inputs

Inputs

(Level 1)

(Level 2)

(Level 3)

Total

Assets:

Cash equivalents:

Money market funds

$

72,304

$

$

$

72,304

U.S. treasury bills

20,367

20,367

Total cash equivalents

92,671

92,671

Investment in equity securities

3,529

3,529

Exarafenib milestone asset (Note 6)

3,214

3,214

Total financial assets

$

96,200

$

$

3,214

$

99,414

Liabilities:

Exarafenib milestone contingent consideration (Note 6)

$

$

$

3,214

$

3,214

Total financial liabilities

$

$

$

3,214

$

3,214